Slide 1
Slide 1
Slide 1

The Product(s)

IMvea is the first non-invasive In Vitro diagnostic assay that can detect rejection, after organ or tissue transplantation. IMvea measures the presence (or absence) of a specific peptide in a sample of human serum tested against a control sample. This detection is made possible by using polyclonal and/or monoclonal antibodies specifically directed against our specific peptide.

The antibodies that were used for the In Vitro monitoring of patients showed the existence of a relationship between the conditions of grafted patients and the presence of this particular protein in their serum. Biovialife has three tests at different stages to help detect rejection.

  • IMveaIH: A reactive kit to diagnose with IHC technique; it would be made of primary monoclonal or polyclonal antibodies tested against a specific peptide. These antibodies would be supplied as reagents and would allow the staining of fixed tissue materials: kidneys, hearts, bone marrow, etc…
  • IMveaQL: A qualitative fast reading diagnosis system based on small stripes equipment. This system will allow practitioners to identify the protein observed during rejection cases. The small stripes are to be placed in a mini tube containing a migration reactive and the patient serum.
  • IMveaQT: A quantitative diagnosis system made of standardized micro plates that will use the ELISA sandwich testing technique.